GCIAvacta: Paul Hill discusses the Clinical validation of their AffiDX Lateral Flow Test & Glen Goodman on Crypto
If you find this podcast useful please give it a rating and review on iTunes by clicking here
On today's Vox Markets Podcast: Avacta: Paul Hill discusses the Clinical validation of their AffiDX Lateral Flow Test & Glen Goodman on Crypto
Paul Hill discusses the Clinical validation of Avacta's #AVCT AffiDX Lateral Flow Test which shows 100% clinical sensitivity for samples with PCR Ct values up to 27.
Avacta Group is developing powerful diagnostics and novel cancer immunotherapies based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
Glen Goodman, former ITV News Business correspondent and now author of, "The Crypto Trader", covers this week’s Bitcoin, Blockchain and Cryptocurrency news. Crypto's mentioned include: $BTC $DODG $ETH $NMR $ALGO $ANKR $NKN $ENJ $NU $OXT #DNT
(Interview starts 14 minutes 38 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.